Disclosed herein are methods of inhibiting nuclear pore complex assembly and inducing nuclear pore complex disassembly. Methods to screen for agents that inhibit nuclear pore assembly or induce nuclear pore complex disassembly are also disclosed.

Disclosed herein are methods of inhibiting nuclear pore complex assembly and inducing nuclear pore complex disassembly. Methods to screen for agents that inhibit nuclear pore assembly or induce nuclear pore complex disassembly are also disclosed.

Disclosed are compositions and methods for targeted treatment of TLR9-expressing cancers, such as primary human MDS progenitors and hematopoietic stem cell (HSC), as well as lung and breast cancers. In particular, multispecific, multivalent antibodies are disclosed that are able to engage T-cells to destroy TLR9-expressing malignant cells.

Disclosed are compositions and methods for targeted treatment of TLR9-expressing cancers, such as primary human MDS progenitors and hematopoietic stem cell (HSC), as well as lung and breast cancers. In particular, multispecific, multivalent antibodies are disclosed that are able to engage T-cells to destroy TLR9-expressing malignant cells.

According to the present invention there are provided methods of regulating the immune system of a companion animal and methods of improving the digestion of a companion animal, wherein each of said methods comprises administering to a companion animal a probiotic bacteria strain of the genus Bifidobacteria.

The present invention relates to an FGFR4 inhibitor having a structure represented by formula (I), preparation method therefor, and applications thereof. A series of compounds represented by formula (I) in the present invention have very-strong inhibition effect on the activity of FGFR4 kinase, have very-high selectivity, can be widely used in the preparation of drugs for treating cancers, specially a liver cancer, a stomach cancer, a prostate cancer, a skin cancer, an ovarian cancer, a lung cancer, a breast cancer or a colon cancer, and can be developed into a new-generation FGFR4 inhibitor drug. ##STR00001##

The present invention relates to an FGFR4 inhibitor having a structure represented by formula (I), preparation method therefor, and applications thereof. A series of compounds represented by formula (I) in the present invention have very-strong inhibition effect on the activity of FGFR4 kinase, have very-high selectivity, can be widely used in the preparation of drugs for treating cancers, specially a liver cancer, a stomach cancer, a prostate cancer, a skin cancer, an ovarian cancer, a lung cancer, a breast cancer or a colon cancer, and can be developed into a new-generation FGFR4 inhibitor drug. ##STR00001##

Disclosed are a therapeutic agent for muscular dystrophy employing pluripotent stem cells obtained from dental pulp and a method for preparation thereof. The therapeutic agent for muscular dystrophy comprises pluripotent stem cell-enriched human dental pulp-derived cells as the active ingredient, and is prepared by a method of preparation comprising the steps of: (a) adding dental pulp-derived cells contained in a dental pulp suspension, in a culture vessel containing feeder cells whose proliferative ability is suppressed, onto a membrane having micropores that can block feeder cells from passing therethrough and supported within the vessel in a manner that avoids direct contact of the lower side face thereof with the feeder cells, and culturing the dental pulp-derived cells on the membrane while preventing direct contact with the feeder cells, and (b) recovering the cells having grown on the membrane as the pluripotent stem cell-enriched human dental pulp-derived cells.

Embodiments disclose a device for testing biological specimen. The device includes a sample carrier and a detachable cover. The sample carrier includes a specimen holding area. The detachable cover is placed on top of the specimen holding area. The detachable cover includes a magnifying component configured to align with the specimen holding area. The focal length of the magnifying component is from 0.1 mm to 8.5 mm. The magnifying component has a linear magnification ratio of at least 1.

The present invention provides a method of treating a disorder using a fibromodulin (FMOD) reprogrammed (FReP) cell. The method comprises administering locally to a human being the FReP cell to a site in need thereof of the human being.